Crispr Therapeutics Ag
Clinical trials sponsored by Crispr Therapeutics Ag, explained in plain language.
-
CRISPR's diabetes cell therapy trial ends early
Disease control TerminatedThis early-stage study tested a new cell therapy called VCTX211 in 5 people with long-standing type 1 diabetes. The goal was to see if the implanted cells could safely help the body produce its own insulin again. The trial was stopped early, and results are not yet available.
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
Gene-Edited immune cells take on Hard-to-Treat blood cancers
Disease control TerminatedThis study tested a new treatment called CTX110, which uses CRISPR gene editing to modify donor immune cells to attack cancer. It was for adults with B-cell cancers like non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that had come back or not responded to other treat…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 04:38 UTC